Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055439 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Chimeric Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
- 4
- Study locations
NCT06055439: Recruiting Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Chimeric Therapeutics.
NCT06055439 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Chimeric Therapeutics. The registered enrollment target is 135 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06055439, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Chimeric Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
Primary Outcome
Assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Conditions Studied
Interventions
- BIOLOGICAL CHM-2101 CAR-T cells
Study Locations (4)
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What NCT06055439 shows while recruiting
NCT06055439 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CHM-2101 CAR-T cells is the first listed.
NCT06055439 reports a single indexed study location in Georgia, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06055439 about?
NCT06055439 is a clinical study titled "A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy". The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.
What is the current status of trial NCT06055439?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2024-05-15. Estimated completion is 2027-05.
What conditions does trial NCT06055439 study?
This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors.
What interventions are being tested in trial NCT06055439?
The interventions under investigation include: CHM-2101 CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT06055439?
This trial is sponsored by Chimeric Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055439 being conducted?
This trial has 4 study locations across Georgia, Illinois, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06055439's enrollment target sits among peer trials
135 185th of 381 higher than 194 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI